Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Vesilute is a synthetic bioactive peptide studied in preclinical research for its urinary system regulatory effects. Research has examined its potential to influence gene expression in bladder and prostate tissues, regulate inflammatory markers in chronic aseptic prostatic inflammation, and improve tissue swelling, congestion, and cellular infiltration in affected tissues.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Vesilute
α-Glutamylaspartic Acid
Vesilute (α-Glutamylaspartic acid) is a dipeptide developed as a urological bioregulator in the Khavinson series. It is studied for regulatory effects on bladder and urinary tract tissue in the context of age-related urological dysfunction.
Proposed to act via chromatin binding in urothelial cells and smooth muscle of the bladder and urinary tract, potentially modulating gene expression related to cell renewal, tight junction proteins, and smooth muscle contractile machinery.
Research includes aged animal models of bladder dysfunction and urinary incontinence. Vesilute has been studied as part of multi-bioregulator protocols targeting urological ageing, including in combination with prostate-targeted peptides (Prostamax).
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
